Letolizumab - Misplaced Pages

Monoclonal antibody Pharmaceutical compound

Letolizumab
Monoclonal antibody
Type	Single-chain variable fragment
Source	Humanized (from mouse)
Target	tumor necrosis factor-related activation protein
Clinical data
Other names	BMS-986004
ATC code	none
Identifiers
CAS Number	1450981-87-9
ChemSpider	none
UNII	449MIE2SD6
KEGG	D11122
Chemical and physical data
Formula	C₁₇₃₄H₂₆₈₈N₄₆₆O₅₃₈S₁₀
Molar mass	38991.90 g·mol

Letolizumab (INN; development code BMS-986004) is a humanized monoclonal antibody designed for the treatment of inflammatory diseases.

This drug was developed by Bristol-Myers Squibb.

References

World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116" (PDF). WHO Drug Information. 30 (4).
Budamakuntla L, Shree-Lakshmi HV, Bansal A, Venkatarayaraju SK (2019). "Spotlight on itolizumab in the treatment of psoriasis - current perspectives from India". Psoriasis: Targets and Therapy. 9: 19–27. doi:10.2147/PTT.S154073. PMC 6501705. PMID 31119094.
Statement On A Nonproprietary Name Adopted By The USAN Council - Letolizumab, American Medical Association.

Monoclonal antibodies for the immune system

Immune system

Human	Immunosuppression: Abrilumab Adalimumab Anifrolumab Atorolimumab Avelumab Avdoralimab Belimumab Bleselumab Brodalumab Camidanlumab tesirine Carlumab Cemiplimab Dupilumab Eldelumab Emapalumab Fresolimumab Golimumab Ianalumab Lanadelumab Lenzilumab Lerdelimumab Lirentelimab Lirilumab Mavrilimumab Metelimumab Morolimumab Namilumab Oleclumab Oxelumab§ Pamrevlumab Placulumab Relatlimab Sarilumab Sifalimumab Tabalumab Tezepelumab Ulocuplumab Varlilumab Immune activation: Ipilimumab Durvalumab Nivolumab Tremelimumab Urelumab Other: Bertilimumab Ontamalimab Zanolimumab Combination: Nivolumab/relatlimab
Mouse	Afelimomab Elsilimomab Faralimomab Gavilimomab Inolimomab Maslimomab Nerelimomab Odulimomab Telimomab aritox Vepalimomab Zolimomab aritox
Chimeric	Andecaliximab Basiliximab Clenoliximab Galiximab Gomiliximab Infliximab Keliximab Lumiliximab Priliximab Teneliximab Vapaliximab
Humanized	Immunosuppressive: Apolizumab Aselizumab Atezolizumab Benralizumab Camrelizumab Cedelizumab Certolizumab pegol Crizanlizumab Daclizumab Eculizumab Efalizumab Epratuzumab Erlizumab Etrolizumab Fontolizumab Frexalimab Inebilizumab Itolizumab Lampalizumab Letolizumab Ligelizumab Lulizumab pegol Mepolizumab Mogamulizumab Natalizumab Ocrelizumab (+hyaluronidase) Omalizumab Ozoralizumab Pascolizumab Pateclizumab Pembrolizumab Pexelizumab Pidilizumab Plozalizumab PRO 140 Quilizumab Ravulizumab Reslizumab Retifanlimab Rontalizumab Rovelizumab Ruplizumab Samalizumab Satralizumab Siplizumab Spartalizumab Talizumab Teclistamab Teplizumab Tislelizumab Tocilizumab Toralizumab Tregalizumab Vatelizumab Vedolizumab Visilizumab Vobarilizumab TGN1412 Immune activation: Dostarlimab Other: Ibalizumab
Chimeric + humanized	Otelixizumab Rozanolixizumab Sutimlimab

Interleukin

Human	Bermekimab Brazikumab Briakinumab Canakinumab Fezakinumab Fletikumab Guselkumab Secukinumab Sirukumab Tralokinumab Ustekinumab
Humanized	Anrukinzumab Bimekizumab Clazakizumab Gevokizumab Ixekizumab Mirikizumab Lebrikizumab Olokizumab Perakizumab Risankizumab Spesolimab Tildrakizumab
Veterinary	Lokivetmab

Inflammatory lesions

Mouse	Besilesomab Fanolesomab Lemalesomab Sulesomab

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

This monoclonal antibody–related article is a stub. You can help Misplaced Pages by expanding it.

Categories: